Literature DB >> 26381727

Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.

Vinit V Patil1,2,3,4, Miguel Guzman4, Angela N Carter5,2,3, Geetanjali Rathore6, Daniel Yoshor7, Daniel Curry7, Angus Wilfong8,6, Satish Agadi8,6, John W Swann5,6,1,2,3, Adekunle M Adesina9, Meenakshi B Bhattacharjee10, Anne E Anderson8,5,6,1,2,3.   

Abstract

Neuropathology of resected brain tissue has revealed an association of focal cortical dysplasia (FCD) with drug-resistant epilepsy (DRE). Recent studies have shown that the mechanistic target of rapamycin (mTOR) pathway is hyperactivated in FCD as evidenced by increased phosphorylation of the ribosomal protein S6 (S6) at serine 240/244 (S(240/244) ), a downstream target of mTOR. Moreover, extracellular regulated kinase (ERK) has been shown to phosphorylate S6 at serine 235/236 (S(235/236) ) and tuberous sclerosis complex 2 (TSC2) at serine 664 (S(664) ) leading to hyperactive mTOR signaling. We evaluated ERK phosphorylation of S6 and TSC2 in two types of FCD (FCD I and FCD II) as a candidate mechanism contributing to mTOR pathway dysregulation. Tissue samples from patients with tuberous sclerosis (TS) served as a positive control. Immunostaining for phospho-S6 (pS6(240/244) and pS6(235/236) ), phospho-ERK (pERK), and phospho-TSC2 (pTSC2) was performed on resected brain tissue with FCD and TS. We found increased pS6(240/244) and pS6(235/236) staining in FCD I, FCD II and TS compared to normal-appearing tissue, while pERK and pTSC2 staining was increased only in FCD IIb and TS tissue. Our results suggest that both the ERK and mTOR pathways are dysregulated in FCD and TS; however, the signaling alterations are different for FCD I as compared to FCD II and TS.
© 2015 Japanese Society of Neuropathology.

Entities:  

Keywords:  Drug-resistant epilepsy (DRE); Extracellular regulated kinase (ERK); focal cortical dysplasia (FCD); mechanistic target of rapamycin (mTOR); tuberous sclerosis (TS)

Mesh:

Substances:

Year:  2015        PMID: 26381727      PMCID: PMC5458727          DOI: 10.1111/neup.12242

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  73 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

2.  The "megalencephaly-capillary malformation" (MCAP) syndrome: the nomenclature of a highly recognizable multiple congenital anomaly syndrome.

Authors:  Ghayda M Mirzaa; William B Dobyns
Journal:  Am J Med Genet A       Date:  2013-06-24       Impact factor: 2.802

3.  Neuropathologic measurements in focal cortical dysplasias: validation of the ILAE 2011 classification system and diagnostic implications for MRI.

Authors:  Angelika Mühlebner; Roland Coras; Katja Kobow; Martha Feucht; Thomas Czech; Hermann Stefan; Daniel Weigel; Michael Buchfelder; Hans Holthausen; Tom Pieper; Manfred Kudernatsch; Ingmar Blümcke
Journal:  Acta Neuropathol       Date:  2011-11-27       Impact factor: 17.088

Review 4.  Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.

Authors:  Paolo Curatolo
Journal:  Pediatr Neurol       Date:  2014-11-20       Impact factor: 3.372

Review 5.  mTOR: A pathogenic signaling pathway in developmental brain malformations.

Authors:  Peter B Crino
Journal:  Trends Mol Med       Date:  2011-09-02       Impact factor: 11.951

6.  Challenges in the surgical treatment of epilepsy patients with cortical dysplasia.

Authors:  Gary W Mathern
Journal:  Epilepsia       Date:  2009-10       Impact factor: 5.864

7.  Animal models of focal cortical dysplasia and tuberous sclerosis complex: recent progress toward clinical applications.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10       Impact factor: 5.864

8.  mTOR cascade activation distinguishes tubers from focal cortical dysplasia.

Authors:  Marianna Baybis; Jia Yu; Allana Lee; Jeff A Golden; Howard Weiner; Guy McKhann; Eleonora Aronica; Peter B Crino
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

9.  Neuron-specific enolase-cre mouse line with cre activity in specific neuronal populations.

Authors:  Chang-Hyuk Kwon; Jing Zhou; Yanjiao Li; Ki Woo Kim; Lori L Hensley; Suzanne J Baker; Luis F Parada
Journal:  Genesis       Date:  2006-03       Impact factor: 2.487

10.  The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase.

Authors:  Shunsuke Mori; Shigeyuki Nada; Hironobu Kimura; Shoji Tajima; Yusuke Takahashi; Ayaka Kitamura; Chitose Oneyama; Masato Okada
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

View more
  5 in total

Review 1.  Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.

Authors:  Kim M Keppler-Noreuil; Victoria E R Parker; Thomas N Darling; Julian A Martinez-Agosto
Journal:  Am J Med Genet C Semin Med Genet       Date:  2016-11-18       Impact factor: 3.908

2.  Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex.

Authors:  Lena H Nguyen; Steven C Leiser; Dekun Song; Daniela Brunner; Steven L Roberds; Michael Wong; Angelique Bordey
Journal:  Epilepsy Res       Date:  2022-02-18       Impact factor: 3.045

3.  Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy.

Authors:  Delia M Talos; Leah M Jacobs; Sarah Gourmaud; Carlos A Coto; Hongyu Sun; Kuei-Cheng Lim; Timothy H Lucas; Kathryn A Davis; Maria Martinez-Lage; Frances E Jensen
Journal:  Ann Neurol       Date:  2018-02-15       Impact factor: 10.422

4.  Clinical and immunohistochemical characteristics of type II and type I focal cortical dysplasia.

Authors:  Kun Yao; Zejun Duan; Jian Zhou; Lin Li; Feng Zhai; Yanting Dong; Xiaoyan Wang; Zhong Ma; Yu Bian; Xueling Qi; Liang Li
Journal:  Oncotarget       Date:  2016-11-22

5.  Genome-wide DNA Methylation and RNAseq Analyses Identify Aberrant Signalling Pathways in Focal Cortical Dysplasia (FCD) Type II.

Authors:  Aparna Banerjee Dixit; Devina Sharma; Manjari Tripathi; Arpna Srivastava; Debasmita Paul; Deepak Prakash; Chitra Sarkar; Krishan Kumar; Jyotirmoy Banerjee; P Sarat Chandra
Journal:  Sci Rep       Date:  2018-12-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.